| Cancer‐associated myositis: clinical features and prognostic signs A Ponyi, T Constantin, M Garami, C András, B Tállai, A Váncsa, L Gergely, ... Annals of the New York Academy of Sciences 1051 (1), 64-71, 2005 | 197 | 2005 |
| Malignant lymphoma-associated autoimmune diseases–a descriptive epidemiological study L Váróczy, L Gergely, M Zeher, G Szegedi, Á Illés Rheumatology international 22, 233-237, 2002 | 175 | 2002 |
| Characteristics of interstitial lung disease in SS-A positive/Jo-1 positive inflammatory myopathy patients A Váncsa, I Csípő, J Németh, K Dévényi, L Gergely, K Dankó Rheumatology international 29, 989-994, 2009 | 168 | 2009 |
| Functional outcome and quality of life in adult patients with idiopathic inflammatory myositis A Ponyi, G Borgulya, T Constantin, A Váncsa, L Gergely, K Dankó Rheumatology 44 (1), 83-88, 2005 | 160 | 2005 |
| Myositis-specific and myositis-associated antibodies in overlap myositis in comparison to primary dermatopolymyositis: relevance for clinical classification: retrospective … A Váncsa, L Gergely, A Ponyi, G Lakos, J Németh, P Szodoray, K Dankó Joint Bone Spine 77 (2), 125-130, 2010 | 95 | 2010 |
| Altered cytokine expression of peripheral blood lymphocytes in polymyositis and dermatomyositis M Aleksza, A Szegedi, P Antal-Szalmás, B Irinyi, L Gergely, A Ponyi, ... Annals of the rheumatic diseases 64 (10), 1485-1489, 2005 | 77 | 2005 |
| Longterm effects of rituximab on B cell counts and autoantibody production in rheumatoid arthritis: use of high-sensitivity flow cytometry for more sensitive assessment of B … A Váncsa, Z Szabó, S Szamosi, N Bodnár, E Végh, L Gergely, G Szűcs, ... The Journal of rheumatology 40 (5), 565-571, 2013 | 46 | 2013 |
| Successful treatment of B cell chronic lymphocytic leukemia-associated severe paraneoplastic pemphigus with cyclosporin A L Gergely, L Váróczy, G Vadász, É Remenyik, Á Illés Acta haematologica 109 (4), 202-205, 2003 | 43 | 2003 |
| Incidence of lymphoma in systemic sclerosis: a retrospective analysis of 218 Hungarian patients with systemic sclerosis É Szekanecz, S Szamosi, L Gergely, P Keszthelyi, Z Szekanecz, G Szűcs Clinical rheumatology 27, 1163-1166, 2008 | 33 | 2008 |
| Epidural malignant lymphomas of the spine: collected experiences with epidural malignant lymphomas of the spinal canal and their treatment G Székely, Z Miltényi, G Mezey, Z Simon, J Gyarmati, L Gergely, L Bognár, ... Spinal Cord 46 (4), 278-281, 2008 | 32 | 2008 |
| A simplified method for Ca2+ flux measurement on isolated human B cells that uses flow cytometry L Gergely, L Cook, V Agnello Clinical Diagnostic Laboratory Immunology 4 (1), 70-74, 1997 | 30 | 1997 |
| Intracellular IL‐4/IFN‐gamma producing peripheral T lymphocyte subsets in B cell non‐Hodgkin's lymphoma patients L Gergely, M Aleksza, L Váróczy, A Ponyi, S Sipka, Á Illés, G Szegedi European journal of haematology 72 (5), 336-341, 2004 | 28 | 2004 |
| Fc-gamma-receptor IIIa polymorphism and gene expression profile do not predict the prognosis in diffuse large B-cell lymphoma treated with R-CHOP protocol L Váróczy, E Zilahi, Á Gyetvai, B Kajtár, L Gergely, S Sipka, Á Illés Pathology & Oncology Research 18, 43-48, 2012 | 25 | 2012 |
| Screening and monitoring of the BTKC481S mutation in a real‐world cohort of patients with relapsed/refractory chronic lymphocytic leukaemia during ibrutinib … C Bödör, L Kotmayer, T László, F Takács, G Barna, R Kiss, E Sebestyén, ... British Journal of Haematology 194 (2), 355-364, 2021 | 22 | 2021 |
| Diagnostics and treatment of pulmonary BALT lymphoma: a report on four cases L Varoczy, L Gergely, A Illes Annals of hematology 82, 363-366, 2003 | 22 | 2003 |
| Malignant lymphomas and autoimmunity—a single center experience from Hungary L Váróczy, E Páyer, Z Kádár, L Gergely, Z Miltényi, F Magyari, P Szodoray, ... Clinical rheumatology 31, 219-224, 2012 | 19 | 2012 |
| Interim PET/CT in diffuse large B-cell lymphoma may facilitate identification of good-prognosis patients among IPI-stratified patients R Nyilas, B Farkas, RR Bicsko, F Magyari, LI Pinczes, A Illes, L Gergely International Journal of Hematology 110, 331-339, 2019 | 15 | 2019 |
| Successful rituximab-CHOP treatment of systemic lupus erythematosus associated with diffuse large B-cell non-Hodgkin lymphoma Z Simon, T Tarr, Z Ress, L Gergely, E Kiss, A Illes Rheumatology International 28, 179-183, 2007 | 15 | 2007 |
| Can CD3+/HLA-DR+ activated T cells predict the prognosis of non-Hodgkin's lymphoma patients? L Váróczy, L Gergely, Z Miltényi, M Aleksza, Á Illés Immunology letters 97 (1), 155-157, 2005 | 14 | 2005 |
| Landscape of BCL2 Resistance Mutations in a Real-World Cohort of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax L Kotmayer, T László, G Mikala, R Kiss, L Lévay, LL Hegyi, S Gróf, T Nagy, ... International Journal of Molecular Sciences 24 (6), 5802, 2023 | 13 | 2023 |
a illesUniversity of DebrecenEmail verificata su med.unideb.hu
